Ethosuximide (Zarontin)
ethosuximide — succinimide anticonvulsant (alpha-ethyl-alpha-methyl-succinimide)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Absence (petit mal) epilepsy | ≥3 years | Monotherapy or combination with other AEDs when other seizure types coexist | FDA Approved |
Ethosuximide is the first-line treatment for childhood absence epilepsy (CAE), the most common pediatric epilepsy syndrome. It selectively suppresses the paroxysmal 3 Hz spike-and-wave discharges that underlie absence seizures by blocking thalamic T-type calcium channels. The landmark Glauser 2010 NEJM trial (N=453) established Class I evidence that ethosuximide is the optimal initial monotherapy for CAE, demonstrating equivalent efficacy to valproic acid and superiority over lamotrigine, with fewer adverse attentional effects than valproic acid. Ethosuximide is not effective against generalized tonic-clonic, focal, or myoclonic seizures, and when used alone in mixed epilepsy, it may increase the frequency of grand mal seizures. Zarontin may be administered in combination with other anticonvulsants when other seizure types coexist with absence epilepsy.
Myoclonic seizures (refractory): Occasionally used as adjunctive therapy for myoclonic seizures unresponsive to first-line agents. Evidence quality: Low (case series only).
Atypical absence seizures: May be tried in atypical absence seizures associated with Lennox-Gastaut syndrome, though response is generally poor compared to typical absence. Evidence quality: Low.
Dosing
Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Childhood absence epilepsy — age 3–5 years | 250 mg/day | Titrate to 20 mg/kg/day (optimal) | 1,500 mg/day (under strict supervision) | Increase by 250 mg every 4–7 days until seizure control 20 mg/kg/day produces therapeutic levels of 40–100 mcg/mL (FDA PI) |
| Childhood absence epilepsy — age ≥6 years | 500 mg/day | Titrate to 20 mg/kg/day (optimal) | 1,500 mg/day (under strict supervision) | Given once daily or in 2 divided doses; increase by 250 mg every 4–7 days May give with food to reduce GI side effects |
| Adult absence epilepsy | 500 mg/day | 500–1,500 mg/day in 1–2 divided doses | 1,500 mg/day (under strict supervision) | Titrate by 250 mg every 4–7 days guided by clinical response and TDM Target serum level 40–100 mcg/mL; levels up to 150 mcg/mL without toxicity reported |
| Absence epilepsy with coexisting seizure types | Per age-appropriate starting dose above | Titrate to 20 mg/kg/day | 1,500 mg/day | Must combine with another AED covering generalized tonic-clonic seizures (e.g., valproate) Ethosuximide alone may worsen GTC seizures in mixed epilepsy |
| Renal impairment | No adjustment if CrCl >30 mL/min | Caution and low initial doses if CrCl <30 mL/min | Guided by TDM | 10–20% excreted unchanged renally; removed by hemodialysis May need supplemental doses around hemodialysis sessions |
Gastrointestinal side effects (nausea, vomiting, abdominal pain, anorexia) are the most common adverse effects of ethosuximide and the leading cause of early discontinuation. These effects are often dose-related and can be substantially reduced by slow titration (250 mg increments every 4–7 days), administering doses with food, and using divided dosing. Most GI symptoms are transient and improve with continued use. The liquid formulation (250 mg/5 mL) allows finer dose adjustments in young children but has a notably bitter taste that can affect compliance.
Pharmacology
Mechanism of Action
Ethosuximide exerts its antiseizure effect by selectively blocking low-threshold T-type (transient) calcium channels, particularly the Cav3.2 (alpha-1H) subtype, in thalamic relay neurons. These channels are essential for generating the rhythmic thalamocortical oscillations that produce the characteristic 3 Hz spike-and-wave discharges on EEG during absence seizures. By inhibiting T-type calcium current, ethosuximide suppresses the paroxysmal burst-firing of thalamic neurons and prevents the synchronization between thalamic and cortical circuits that underlies the brief lapses of consciousness in absence epilepsy. This selective mechanism explains both its high efficacy against absence seizures and its lack of activity against other seizure types that arise from different neuronal circuits and channel mechanisms.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Complete oral absorption; bioavailability ~100%; Tmax ~4 h (single dose); capsule and solution bioequivalent (solution absorbed slightly faster) | Rapid and complete absorption allows reliable oral dosing; can be taken with or without food (food may reduce GI upset without affecting total absorption) |
| Distribution | Vd ~0.7 L/kg; protein binding negligible (<10%); distributes into saliva, breast milk, and across the placenta | Negligible protein binding means drug interactions via protein displacement are unlikely; saliva levels approximate serum levels and can be used for non-invasive TDM |
| Metabolism | Hepatic oxidation primarily via CYP3A4 (minor CYP2E1 contribution); metabolized to hydroxylated metabolite then conjugated to glucuronide; no active metabolites | CYP3A4 substrate means levels can be affected by strong CYP3A4 inhibitors (increase levels) and inducers (decrease levels); ethosuximide itself does not significantly induce or inhibit hepatic enzymes |
| Elimination | t½ ~30 h in children, 50–60 h in adults; 10–20% excreted unchanged in urine; up to 50% excreted as hydroxylated metabolite and glucuronide conjugate; removed by hemodialysis; first-order kinetics | Long half-life supports once-daily dosing in many patients; steady state reached in approximately 4–7 days at usual dosage; children clear ethosuximide faster than adults, so may need higher per-kg doses or divided dosing |
Side Effects
Ethosuximide was approved in the 1960s, before standardized adverse-event reporting in registration trials. The adverse effects listed below are derived from the FDA-approved labeling, post-marketing surveillance, and decades of clinical experience. The Glauser 2010 NEJM trial provides the best comparative tolerability data: ethosuximide and valproic acid had similar discontinuation rates due to adverse events, but ethosuximide caused significantly less attentional dysfunction (33% vs 49%). Gastrointestinal symptoms are the most common reason for intolerance.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea and vomiting | Very common (GI symptoms described as "frequent" in PI) | Most common adverse effect; dose-related; improves with slow titration, food administration, and divided dosing |
| Anorexia / weight loss | Very common | GI-related; usually transient; monitor weight and nutritional status in children |
| Abdominal pain / cramps | Very common (epigastric and abdominal pain) | Take with food to minimize; often dose-related and improves over time |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Drowsiness / lethargy | Common | Dose-related; usually transient; caution with driving and operating machinery |
| Headache | Common | Usually mild and self-limiting |
| Dizziness | Common | Dose-related; assess with serum levels if persistent |
| Hiccups | Common | Unique and relatively specific to succinimide anticonvulsants |
| Diarrhea | Common | Part of the GI adverse effect profile; usually dose-related |
| Irritability / hyperactivity (children) | Common in children | Behavioral effects particularly in patients with pre-existing psychological abnormalities (FDA PI) |
| Fatigue / ataxia | Common | CNS effects; may indicate supratherapeutic levels |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Blood dyscrasias (leukopenia, agranulocytosis, pancytopenia) | Rare; fatal outcomes reported | Variable; may present as infection | Periodic blood counts mandatory; obtain CBC immediately if signs of infection (sore throat, fever) develop; discontinue if significant blood dyscrasia confirmed |
| Stevens-Johnson Syndrome (SJS) | Rare; can be fatal | Usually within 28 days; can occur later | Discontinue at first sign of rash unless clearly not drug-related; never rechallenge; dermatology consultation |
| Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) | Rare | 2–8 weeks after initiation | Discontinue immediately if fever, rash, and lymphadenopathy develop with eosinophilia; evaluate even if rash is not evident |
| Systemic Lupus Erythematosus (drug-induced SLE) | Rare | Months to years | Monitor for joint pain, rash, serositis; check ANA if SLE suspected; discontinue ethosuximide and manage SLE |
| Psychiatric disturbance (paranoid psychosis, depression with suicidal intent) | Rare (more common in patients with prior psychiatric history) | Variable | Monitor mood and behavior; AED class warning for suicidality applies; psychiatric evaluation if symptoms emerge |
| Hepatic and renal toxicity | Rare | Variable | Periodic LFTs and urinalysis recommended; ethosuximide can produce morphological and functional changes in the liver (FDA PI); administer with extreme caution in hepatic or renal disease |
| Suicidal behavior and ideation | AED class effect (RR 1.8 vs placebo) | As early as 1 week | AED class warning; monitor for depression, mood changes, suicidal ideation |
Fatal blood dyscrasias including agranulocytosis and pancytopenia have been reported with ethosuximide. Patients must be instructed to immediately report any signs of infection such as sore throat, fever, or mucosal ulceration, as these may be the first manifestation of potentially life-threatening bone marrow suppression. CBC should be obtained promptly in any patient presenting with signs of infection, and ethosuximide should be discontinued if a significant blood dyscrasia is confirmed. Periodic blood counts are mandatory throughout therapy.
Drug Interactions
Ethosuximide is metabolized primarily by CYP3A4 and, unlike phenobarbital or carbamazepine, does not significantly induce or inhibit hepatic cytochrome P450 enzymes. This favorable interaction profile is one of its clinical advantages. However, as a CYP3A4 substrate, its levels can be altered by strong CYP3A4 inducers (which decrease ethosuximide levels) and inhibitors (which increase levels). The FDA PI specifically notes interactions with phenytoin and valproic acid.
Unlike phenobarbital, carbamazepine, and phenytoin, ethosuximide does not induce hepatic cytochrome P450 enzymes. This means it does not decrease the efficacy of oral contraceptives, warfarin, or immunosuppressants — a significant practical advantage for patients who require these concomitant therapies. This non-inducing property also simplifies polytherapy regimens in epilepsy, as co-administered drugs maintain their expected plasma levels.
Monitoring
-
Serum Ethosuximide Level
After reaching steady state (~4–7 days); after dose changes; periodically
Routine Therapeutic range 40–100 mcg/mL. Levels below 40 mcg/mL are rarely effective. Levels up to 150 mcg/mL have been tolerated without signs of toxicity, though the relationship between level and toxicity is not well defined. Optimal pediatric dose of 20 mg/kg/day targets this therapeutic range (FDA PI). -
Complete Blood Count (CBC)
Baseline, then periodically; urgently if infection signs develop
Routine Blood dyscrasias with fatal outcome have been reported. Obtain CBC immediately if patient develops sore throat, fever, mucosal ulceration, or other signs of infection. Periodic counts are recommended even in asymptomatic patients (FDA PI). -
Hepatic Function (LFTs)
Baseline, then periodically
Routine FDA PI states ethosuximide is capable of producing morphological and functional changes in the liver. Abnormal liver function studies have been reported. Administer with extreme caution in known liver disease. -
Urinalysis
Baseline, then periodically
Routine Periodic urinalysis is advised by the FDA PI. Abnormal renal function studies have been reported. Microscopic hematuria is a recognized adverse effect. -
Weight and Nutritional Status
Each visit (especially in children)
Routine Anorexia and weight loss are common GI side effects. Monitor growth parameters in pediatric patients as this population is the primary user of ethosuximide. -
Mood and Suicidality
Every visit, ongoing
Routine AED class warning applies. Rare psychiatric disturbances including depression with suicidal intentions reported, particularly in patients with pre-existing psychological abnormalities. -
Skin Assessment (SJS/DRESS)
First 28 days after initiation (highest risk) and ongoing
Trigger-based Discontinue at first sign of rash unless clearly not drug-related. Counsel patients and caregivers to report any new skin eruption immediately. SJS onset usually within 28 days but can occur later. -
Concomitant Drug Levels
When adding or adjusting ethosuximide with other AEDs
Trigger-based Monitor phenytoin levels (ethosuximide may elevate them) and valproic acid levels (bidirectional interaction) when co-prescribed. FDA PI advises periodic serum level determinations of both drugs.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to succinimides — the sole absolute contraindication listed in the FDA PI
Relative Contraindications (Specialist Input Recommended)
- Known liver disease — ethosuximide is hepatically metabolized and can produce liver changes; administer with extreme caution (FDA PI)
- Known renal disease — 10–20% excreted unchanged renally; administer with extreme caution (FDA PI)
- Mixed epilepsy without concurrent AED coverage for GTC seizures — ethosuximide monotherapy may increase grand mal seizure frequency in mixed epilepsy; must be combined with a broad-spectrum AED
- Pregnancy — ethosuximide crosses placenta; birth defects reported; weigh benefits against risks; enroll in NAAED Pregnancy Registry
Use with Caution
- Patients with pre-existing psychiatric abnormalities — behavioral and psychiatric disturbances (including psychosis) may be exacerbated
- Nursing mothers — ethosuximide is excreted in human breast milk; effects on the nursing infant are unknown; use only if benefits clearly outweigh risks
- Children under 3 years — safety and effectiveness below age 3 have not been established
Antiepileptic drugs, including Zarontin, increase the risk of suicidal thoughts or behavior. Pooled analysis of 199 placebo-controlled trials of 11 AEDs showed approximately twice the risk (adjusted RR 1.8; 95% CI: 1.2–2.7) in AED-treated patients compared to placebo. The estimated incidence was 0.43% in drug-treated vs 0.24% in placebo-treated patients. Monitor for emergence or worsening of depression, suicidal thoughts, or unusual behavioral changes.
Patient Counselling
Purpose of Therapy
Ethosuximide is a medication that prevents absence seizures — the brief "staring spells" or lapses in awareness that occur in certain types of epilepsy. It specifically targets the brain activity pattern responsible for these episodes. This medicine only works for absence seizures; it does not prevent other seizure types such as convulsions. If your child or you have other types of seizures in addition to absence seizures, your doctor will prescribe an additional medication to cover those.
How to Take
Ethosuximide comes as capsules (250 mg) or a liquid (250 mg per teaspoon). It can be taken once daily or split into two doses. Taking it with food or a snack reduces stomach upset, which is the most common side effect. The liquid has a bitter taste; mixing it with a flavored drink may help children take it more easily. Never change the dose or stop the medication without talking to your doctor first, as stopping suddenly could trigger a cluster of seizures.
Sources
- Zarontin (ethosuximide) Capsules, USP. Full Prescribing Information. NDA 012380/S-034. Pfizer Inc. Revised March 2012. FDA Label Primary US prescribing information for ethosuximide capsules, including dosing, contraindications, warnings, drug interactions, and the complete adverse reactions list.
- Zarontin (ethosuximide) Oral Solution. Full Prescribing Information. NDA 080258/S-025. Pfizer Inc. FDA Label Prescribing information for ethosuximide oral solution formulation (250 mg/5 mL), with identical clinical content to the capsule label.
- Glauser TA, Cnaan A, Shinnar S, et al; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790–799. doi:10.1056/NEJMoa0902014 Landmark double-blind RCT (N=453). Freedom-from-failure at 16 weeks: ETX 53%, VPA 58%, LTG 29%. Attentional dysfunction less with ETX (33%) than VPA (49%). First Class I evidence for any generalized seizure treatment.
- Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141–155. doi:10.1111/epi.12028 12-month follow-up of the CAE trial. ETX and VPA maintained similar freedom-from-failure rates (45% and 44%), both superior to LTG (21%). Confirms ethosuximide as optimal initial monotherapy for CAE.
- Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2021;1(1):CD003032. doi:10.1002/14651858.CD003032.pub5 Cochrane systematic review confirming ethosuximide and valproic acid as similarly effective for absence seizures; ethosuximide preferred due to fewer attentional effects.
- Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563. doi:10.1111/epi.12074 ILAE evidence review assigning ethosuximide Level A (established efficacy) for childhood absence epilepsy as initial monotherapy.
- Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68:18–34. doi:10.1016/j.pediatrneurol.2017.01.025 Consensus panel noting ethosuximide as a potential adjunctive therapy for absence and myoclonic components in certain genetic epilepsy syndromes.
- Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989;25(6):582–593. doi:10.1002/ana.410250610 Seminal electrophysiology study demonstrating that ethosuximide reduces the T-type calcium current in thalamic relay neurons, establishing the mechanistic basis for its anti-absence activity.
- Manning JP, Richards DA, Leresche N, Crunelli V, Bhakoo KK. Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience. 2004;123(1):5–9. doi:10.1016/j.neuroscience.2003.09.026 Demonstrates cortical-area-specific suppression of spike-and-wave discharges by ethosuximide in a genetic absence epilepsy model.
- Ethosuximide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. StatPearls Comprehensive clinical pharmacology reference covering mechanism of action, dosing, pharmacokinetics, adverse effects, and monitoring.
- Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet. 1995;29(4):257–286. doi:10.2165/00003088-199529040-00004 Comprehensive review of ethosuximide pharmacokinetics in children, establishing pediatric half-life (~30 hours), optimal dosing of 20 mg/kg/day, and age-related clearance differences.
- Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526–548. doi:10.1097/FTD.0000000000000546 Comprehensive TDM reference confirming ethosuximide therapeutic range of 40–100 mcg/mL and summarizing pharmacokinetic parameters across populations.